Phathom Pharmaceuticals Stock Performance
| PHAT Stock | USD 12.23 0.59 4.60% |
The company holds a Beta of -0.0663, which implies not very significant fluctuations relative to the market. As returns on the market increase, returns on owning Phathom Pharmaceuticals are expected to decrease at a much lower rate. During the bear market, Phathom Pharmaceuticals is likely to outperform the market. At this point, Phathom Pharmaceuticals has a negative expected return of -0.24%. Please make sure to check Phathom Pharmaceuticals' jensen alpha, as well as the relationship between the skewness and day median price , to decide if Phathom Pharmaceuticals performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
Weakest
Weak | Strong |
Over the last 90 days Phathom Pharmaceuticals has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of weak performance in the last few months, the Stock's basic indicators remain comparatively stable which may send shares a bit higher in March 2026. The newest uproar may also be a sign of mid-term up-swing for the firm private investors. ...more
| Begin Period Cash Flow | 384.3 M | |
| Total Cashflows From Investing Activities | -135 K |
Phathom Pharmaceuticals Relative Risk vs. Return Landscape
If you would invest 1,485 in Phathom Pharmaceuticals on November 13, 2025 and sell it today you would lose (262.50) from holding Phathom Pharmaceuticals or give up 17.68% of portfolio value over 90 days. Phathom Pharmaceuticals is currently does not generate positive expected returns and assumes 3.8911% risk (volatility on return distribution) over the 90 days horizon. In different words, 34% of stocks are less volatile than Phathom, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Phathom Pharmaceuticals Target Price Odds to finish over Current Price
The tendency of Phathom Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to move above the current price in 90 days |
| 12.23 | 90 days | 12.23 | about 98.0 |
Based on a normal probability distribution, the odds of Phathom Pharmaceuticals to move above the current price in 90 days from now is about 98.0 (This Phathom Pharmaceuticals probability density function shows the probability of Phathom Stock to fall within a particular range of prices over 90 days) .
Phathom Pharmaceuticals Price Density |
| Price |
Predictive Modules for Phathom Pharmaceuticals
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Phathom Pharmaceuticals. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.Phathom Pharmaceuticals Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. Phathom Pharmaceuticals is not an exception. The market had few large corrections towards the Phathom Pharmaceuticals' value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Phathom Pharmaceuticals, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Phathom Pharmaceuticals within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | -0.25 | |
β | Beta against Dow Jones | -0.07 | |
σ | Overall volatility | 1.36 | |
Ir | Information ratio | -0.09 |
Phathom Pharmaceuticals Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Phathom Pharmaceuticals for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Phathom Pharmaceuticals can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| Phathom Pharmaceuticals generated a negative expected return over the last 90 days | |
| Phathom Pharmaceuticals has high historical volatility and very poor performance | |
| Phathom Pharmaceuticals has a very high chance of going through financial distress in the upcoming years | |
| The company reported the previous year's revenue of 55.25 M. Net Loss for the year was (334.33 M) with profit before overhead, payroll, taxes, and interest of 128.42 M. | |
| Phathom Pharmaceuticals currently holds about 207.39 M in cash with (266.77 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 5.39. | |
| Phathom Pharmaceuticals has a frail financial position based on the latest SEC disclosures | |
| Over 77.0% of the company shares are owned by institutional investors |
Phathom Pharmaceuticals Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Phathom Stock often depends not only on the future outlook of the current and potential Phathom Pharmaceuticals' investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Phathom Pharmaceuticals' indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 63.2 M | |
| Cash And Short Term Investments | 297.3 M |
Phathom Pharmaceuticals Fundamentals Growth
Phathom Stock prices reflect investors' perceptions of the future prospects and financial health of Phathom Pharmaceuticals, and Phathom Pharmaceuticals fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Phathom Stock performance.
| Return On Equity | -34.89 | ||||
| Return On Asset | -0.43 | ||||
| Profit Margin | (1.87) % | ||||
| Operating Margin | (0.31) % | ||||
| Current Valuation | 1.06 B | ||||
| Shares Outstanding | 78.01 M | ||||
| Price To Book | 25.37 X | ||||
| Price To Sales | 6.77 X | ||||
| Revenue | 55.25 M | ||||
| EBITDA | (261.52 M) | ||||
| Cash And Equivalents | 207.39 M | ||||
| Cash Per Share | 5.39 X | ||||
| Total Debt | 554.95 M | ||||
| Debt To Equity | 2.43 % | ||||
| Book Value Per Share | (5.95) X | ||||
| Cash Flow From Operations | (266.77 M) | ||||
| Earnings Per Share | (3.76) X | ||||
| Total Asset | 378.32 M | ||||
| Retained Earnings | (1.26 B) | ||||
About Phathom Pharmaceuticals Performance
Assessing Phathom Pharmaceuticals' fundamental ratios provides investors with valuable insights into Phathom Pharmaceuticals' financial health and overall profitability. This information is crucial for making informed investment decisions. A high ROA would indicate that the Phathom Pharmaceuticals is effectively leveraging its assets and equity to generate significant profits, making it an appealing investment. Conversely, low Return on Assets could signal underlying management issues in assets and equity, indicating a necessity for operational refinements. Please also refer to our technical analysis and fundamental analysis pages.
Phathom Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. Phathom Pharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Florham Park, New Jersey. Phathom Pharmaceuticals operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 77 people.Things to note about Phathom Pharmaceuticals performance evaluation
Checking the ongoing alerts about Phathom Pharmaceuticals for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Phathom Pharmaceuticals help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Phathom Pharmaceuticals generated a negative expected return over the last 90 days | |
| Phathom Pharmaceuticals has high historical volatility and very poor performance | |
| Phathom Pharmaceuticals has a very high chance of going through financial distress in the upcoming years | |
| The company reported the previous year's revenue of 55.25 M. Net Loss for the year was (334.33 M) with profit before overhead, payroll, taxes, and interest of 128.42 M. | |
| Phathom Pharmaceuticals currently holds about 207.39 M in cash with (266.77 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 5.39. | |
| Phathom Pharmaceuticals has a frail financial position based on the latest SEC disclosures | |
| Over 77.0% of the company shares are owned by institutional investors |
- Analyzing Phathom Pharmaceuticals' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Phathom Pharmaceuticals' stock is overvalued or undervalued compared to its peers.
- Examining Phathom Pharmaceuticals' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Phathom Pharmaceuticals' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Phathom Pharmaceuticals' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Phathom Pharmaceuticals' stock. These opinions can provide insight into Phathom Pharmaceuticals' potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Phathom Stock Analysis
When running Phathom Pharmaceuticals' price analysis, check to measure Phathom Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Phathom Pharmaceuticals is operating at the current time. Most of Phathom Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Phathom Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Phathom Pharmaceuticals' price. Additionally, you may evaluate how the addition of Phathom Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.